NAYA Bio (NAYA): Utang-utang marang kapitalisasi buku

NAYA Biosciences maintains its position in the targeted immunotherapy niche, leveraging a debt-free balance sheet and strict cost controls. The company's financial leverage confirms this stability, with 3.81 representing the latest metric reading. Growth is driven by the merger with INVO and the development of reproductive medicine, although high expenses and dilution risks are already priced in by the market.

This indicator determines the financial stability of the business by comparing debt obligations to the market value of equity. The metric measures credit leverage, where fixed debt is weighed against volatile capitalization. By analyzing the historical changes in the debt-to-equity ratio, an investor can track the dynamics of the debt load in real time. An optimal leverage balance prevents resource stagnation. For NAYA Biosciences (NAYA), such stability is critical during the development of the Flex-NK platform in oncology and reproductive medicine.